Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 13.

Weder, B; Mozaffari, M; Biedermann, L; Mamie, C; Moncsek, A; Wang, L; Clarke, S H; Rogler, G; McRae, B L; Graff, C L; Ruiz, P A; Hausmann, Martin (2018). BCL-2 levels do not predict azathioprine treatment response in inflammatory bowel disease, but inhibition induces lymphocyte apoptosis and ameliorates colitis in mice. Clinical and Experimental Immunology, 193(3):346-360.

Lang, B M; Biedermann, L; van Haaften, W T; de Vallière, C; Schuurmans, M; Begré, S; Zeitz, J; Scharl, M; Turina, M; Greuter, T; Schreiner, P; Heinrich, H; Kuntzen, T; Vavricka, S R; Rogler, G; Beerenwinkel, N; Misselwitz, B; Swiss IBD Cohort Study Group (2018). Genetic polymorphisms associated with smoking behaviour predict the risk of surgery in patients with Crohn's disease. Alimentary Pharmacology & Therapeutics, 47(1):55-66.

Greuter, T; Biedermann, L; Rogler, G; Sauter, B; Seibold, F (2016). Alicaforsen, an antisense inhibitor of ICAM-1, as treatment for chronic refractory pouchitis after proctocolectomy: A case series. United European Gastroenterology journal, 4(1):97-104.

Rogler, G; Biedermann, L (2015). Clinical utility of biomarkers in IBD. Current Gastroenterology Reports, 17(7):17:26.

Biedermann, L; Fournier, N; Misselwitz, B; Frei, P; Zeitz, J; Manser, C N; Pittet, V; Juillerat, P; von Känel, R; Fried, M; Vavricka, S R; Rogler, G (2015). High rates of smoking especially in female Crohn's disease patients and low use of supportive measures to achieve smoking cessation-data from the swiss IBD cohort study. Journal of Crohn's & colitis, 9(10):819-829.

Rogler, G; Vavricka, S R; Biedermann, L (2015). Integrating imaging into clinical practice in inflammatory bowel disease. Digestive Diseases, 33 Suppl:37-43.

Barthel, C; Wiegand, S; Scharl, S; Scharl, M; Frei, P; Vavricka, S R; Fried, M; Sulz, M C; Wiegand, N; Rogler, G; Biedermann, L (2015). Patients' perceptions on the impact of coffee consumption in inflammatory bowel disease: friend or foe?--a patient survey. Nutrition Journal, 14:78.

Greuter, T; Lang, S; Holler, E; Hawkey, C J; Rogler, G; Biedermann, L (2015). Serum REG3alpha and C-reactive protein levels in Crohn's disease patients undergoing immunoablation and autologous hemopoetic stem cell transplantation in the ASTIC trial. Digestion, 92(2):83-89.

Rauch, P J; Müllhaupt, B; Biedermann, L; Manz, M G; Ruschitzka, F; Flammer, A; Segerer, S T; Mohebbi, N; Jung, H H; Moch, H; Ikenberg, K; Aguzzi, A; Nuvolone, M; Distler, O; Rauch, A; Fehr, T H; Gerber, B (2014). Systemische Amyloidosen. Swiss Medical Forum, 14(50):943-948.

Biedermann, L; Kerl, K; Rogler, G; Hofbauer, G F L (2013). Drug-induced erythema nodosum after the administration of certolizumab in Crohn's disease. Inflammatory Bowel Diseases, 19(1):E4-6.

Frei, P; Biedermann, L; Rogler, G (2011). Morbus Crohn und Colitis ulcerosa – Wichtiges für den Nicht-Gastroenterologen. Swiss Medical Forum, 11(41):718-726.

Biedermann, L; Schaer, D J; Montani, M; Speich, R; Müllhaupt, B (2009). Extensive chronic xanthogranulomatous intra-abdominal inflammation due to Mycoplasma hominis mimicking a malignancy: a case report. Journal of Medical Case Reports, 3:9211.

Biedermann, L; Fried, M (2008). Obstipation. Praxis, 97(21):1109-1119.

This list was generated on Thu Jun 20 13:12:09 2019 CEST.